1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer

• Status: Terminated
• Trial end date: 2018-05-01
• Target enrollment: 0
• Participant gender: Female

Summary

In first-line metastatic breast cancer, the bevacizumab-taxane to progression or toxicity, is currently the standard treatment. In patients expressing hormone receptors, it was shown that hormone therapy administered in maintenance after induction chemotherapy, could have a benefit regarding the progression-free survival. The investigators make the hypothesis that there would be interest to discontinue treatment with taxane after 4 months, and to begin hormone therapy while continuing maintenance bevacizumab.

Exemestane was chosen because it has been shown potentially active in patients who progressed after letrozole, anastrozole or tamoxifen.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: ARCAGY/ GINECO GROUP
• Treatments: Albumin-Bound Paclitaxel; Bevacizumab; Estrogens; Exemestane; Paclitaxel; Taxane

Criteria

Inclusion Criteria:

• Age > 18 ans.

• Metastatic breast cancer or locally advanced

• RE+, HER2-

• Patient receiving paclitaxel-bevacizumab first line chemotherapy

Exclusion Criteria:

• Previous treatment by exemestane (both in adjuvant or metastatic treatment).

• 1st line of chemotherapy different thaan paclitaxel-bevacizumab.

• Treatment by paclitaxel-bevacizumab > 18 weeks.

• HER2 positifs et/ou récepteurs aux oestrogènes négatifs.

• Previous thrombosis event within the 6 months before inclusion .

• Previous significant surgery within the 28 days before treatment start

• Previuous coagulopathy.